MBAL Dr. Ivan Seliminski - Sliven AD
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Cardiology Department at MBAL Dr. Ivan Seliminski - Sliven AD focuses on innovative strategies to manage atherosclerotic cardiovascular disease and bleeding complications related to anticoagulant therapy. Trials aim to improve surgical outcomes for patients on FXa inhibitors and to evaluate new lipid‑modifying agents that may lower the risk of major adverse CV events.
- Reversal of anticoagulation for urgent surgery
- Evaluation of obicetrapib on cardiovascular event reduction
- Optimization of lipid‑modifying therapy in ASCVD
With 13 investigators conducting four trials, the site contributes valuable data to cardiovascular research in Europe.
Respiratory Tract Diseases
Research in the respiratory area targets persistent asthma that remains uncontrolled despite standard treatment. Studies assess novel inhaled anti‑inflammatory compounds as an add‑on therapy to existing ICS/LABA regimens, seeking to reduce the frequency of asthma exacerbations over a year‑long period.
- Add‑on inhaled therapy to improve asthma control
- Reduction of asthma exacerbation rates
- Safety assessment of new inhaled anti‑inflammatory agents
The department’s multidisciplinary team supports patients in Sliven and the wider Bulgarian region.
Virus Diseases
The site is actively involved in pediatric investigations of emerging antiviral treatments for COVID-19. Trials evaluate the pharmacokinetics and safety of a novel antiviral in children and adolescents, aiming to fill the therapeutic gap for young patients affected by the virus.
- Pharmacokinetic profiling of antiviral in pediatric participants
- Safety and tolerability assessment in children with COVID‑19
- Development of age‑appropriate treatment options
These studies enhance global knowledge of pediatric COVID‑19 management while leveraging the expertise of the local clinical team.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 55 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MBAL Dr. Ivan Seliminski - Sliven AD
lock Showing 1 of 26 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 55 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Trospium Chloride | 4 | Unknown | 2023-03-22 | 2025-11-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.